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be able to analyse as a 'best estimate', since they only want to analyse knee OA, and therefore will need to exclude all studies with hip OA only, hip and knee OA combined and hand OA only? How many subjects would this leave for analysis if they are able to access all available data, and would this achieve the required statistical power? 4. A response to the above queries is likely to assist in the analysis proposed and whether it can be achieved realistically from the available literature. Based on what is written, it is difficult to fully appreciate how the authors could achieve the study aims in a subpopulation with knee OA from published trials without providing further information about the number of participants to be analysed.
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GENERAL COMMENTS
The proposal is certainly about a very relevant topic.
Major point: it is attractive to find different subgroups of OA with differences in subchondral bone, but unfortunately we do not have the instruments to detect differences in subchondral bone, such as high or low bone turnover; other points: -A meta-analysis in more than 3000 bisphosphonate users published in 2018 has a negative result: do the authors expect substantially more favorable results? -I suppose age is also an important effect modifier, and type of bisphosphonate as well (Zol has much more potency than the oral bisphosphonates)
VERSION 1 -AUTHOR RESPONSE
Reviewers' Comments to Author:
Reviewer: 1 Reviewer Name: Nidhi Sofat Institution and Country: Institute for Infection & immunity, St George's, University of London, Cranmer Terrace, London, UK Competing Interests: None declared In this manuscript the authors propose a protocol for evaluating whether bisphosphonates are efficacious in specific groups of people with knee osteoarthritis from specific subpopulations identified from published clinical trials. The authors propose to contact lead authors from published trials of bisphosphonates in knee osteoarthritis and to use anonymised data for analysis from the OA Trial data bank. Although the research question is an interesting one, there are several issues with the way the project has been described to be able to assess whether it will be able to deliver on the question proposed, which are summarised below:
1. As the authors describe themselves, 3 meta-analyses have already been published assessing the efficacy of bisphosphonates in osteoarthritis. So far, all 3 previously published analyses have been inconclusive, reporting issues of heterogeneity in patient populations analysed, differences in outcome measures, including pain and structural damage (most commonly measured as joint space narrowing), differences in doses and duration of bisphosphonates used and differing Ethnic populations in published studies. The reviewer is not convinced that an individual patient data metaanalysis will be achievable based on the published studies available in the literature, for reasons outlined in points 2 and 3 below. Authors' response: We thank the reviewer for the comment. The three conventional meta-analyses previously conducted on this topic reported on the "mean" treatment effects in the overall OA population, while the efficacy of bisphosphonates in selected subpopulations (which may respond different to bisphosphonate therapy) remains unclear in the literature. Shedding light on this question is of utmost importance if we are to move towards tailored care for patients with knee OA, as has been highlighted as an important need in the OA field recently (1). We aim to address this question using a contemporary high-quality research design with important advantages over conventional meta-analysis with aggregate data particularly for this type of research question. The proposed research design using individual patient data allows better standardization of variables across studies and better characterization of subpopulations and outcomes for a more consistent and uniform analysis. This is particularly useful when there is heterogeneity across trials. The outcomes chosen for this study were the ones most commonly used in the previous trials to demonstrate clinical and structural efficacy. The IPD meta-analysis (IPD-MA) design is particularly advantageous for the investigation of potential treatment effect modifiers since the statistical power for subgroup analyses (one of the main problems in subgroup research) is typically larger in IPD-MAs compared to individual studies and conventional meta-analysis with aggregate data. These advantages have been well described by the Cochrane research group which recommends this approach for the investigation of differential treatment effects across subgroups of individuals (2, 3). Several studies have compared the results from IPD-MA against results from conventional metaanalysis using aggregate data and, in several circumstances, the IPD-MAs revealed novel insights related to the main treatment effect as well as potential treatment effect modifiers (3, 4) . Although it is typically more laborious to conduct an IPD-MA, the current project involves an international collaboration and benefits from the expertise and resources of the OA Trial Bank which has experience with this research design (5). Previous IPD-MA conducted by the OA Trial Bank group have shown that glucosamine was not superior to placebo in pre-specified clinically relevant subgroups (6) and that individuals with more severe pain have greater benefits from intra-articular glucocorticoid injection than those with less severe pain when compared to placebo injection (7). We do believe this IPD-MA is necessary and will build upon existing knowledge on the topic to enable potentially novel insights.
2. Can the authors provide any further information on the number of subjects required for analysis to see any significant differences in pain, function and joint space narrowing, which are their reported outcome measures? A pre-specified power calculation of this kind would prove very helpful to assess whether the OA Data Bank and published studies have the information available for the authors to achieve their study aims. Authors' response: We appreciate the reviewer's comment. We agree with the reviewer that a discussion about the total number of participants and trials that will be included in the analyses will be important when interpreting our results. However, sample size calculation in meta-analyses before doing the study is typically not performed since the data has already been collected. A power calculation is also not possible at this point without knowing the number of participants that will be included in our analyses given we have not contacted or heard from the respective individual study investigators as yet. Authors' action: We have added the following sentence to the Methods: "The results will be interpreted taking into account the number of trials and participants included in the analyses and the methodological quality of the trials".
3. Based on previously published studies ~3000 participants were included in previous metaanalyses. In order for the authors to provide a useful contribution to the current literature, can they estimate how many subjects from the published literature they will be able to analyse as a 'best estimate', since they only want to analyse knee OA, and therefore will need to exclude all studies with hip OA only, hip and knee OA combined and hand OA only? How many subjects would this leave for analysis if they are able to access all available data, and would this achieve the required statistical power? Authors' response: Only three out of the eleven studies identified included a mixed population of knee and back pain participants. Without considering these three studies, the summed number of knee OA participants in the other trials is 3192. As mentioned in response to comment number 2, the final number of participants that will be included in the analyses will be taken into account in the discussion and interpretation of our findings.
A response to the above queries is likely to assist in the analysis proposed and whether it can be achieved realistically from the available literature. Based on what is written, it is difficult to fully appreciate how the authors could achieve the study aims in a subpopulation with knee OA from published trials without providing further information about the number of participants to be analysed.
Reviewer: 2
Reviewer Name: WF Lems Institution and Country: VUmc, Amsterdam, the Netherlands Competing Interests: no competing interest
The proposal is certainly about a very relevant topic. 1) Major point: it is attractive to find different subgroups of OA with differences in subchondral bone, but unfortunately we do not have the instruments to detect differences in subchondral bone, such as high or low bone turnover; Authors' response: We appreciate the reviewer's relevant comment. We agree with the reviewer on the fact that the potential treatment effect modifiers that we aim to include in the subgroup analyses are not direct measures of subchondral bone turnover. Due to the lack of such measures available in clinical trials to date, we selected patient and disease level characteristics that may be associated with alterations in systemic and/or subchondral bone metabolism and that could be easily obtainable in clinical and research settings. A few trials have collected information on systemic markers of bone turnover (serum, urinary and bone mineral density) and imaging markers of altered subchondral bone remodeling (bone marrow lesions) which will be included as potential treatment effect modifiers if these data are sufficiently available. Authors' action: We have added a bullet point in the "Strengths and limitations of this study" as follows: "The variables that will be tested as potential treatment effect modifiers are possibly associated with but are not direct measures of distinct rates of subchondral bone turnover". other points: 2) A meta-analysis in more than 3000 bisphosphonate users published in 2018 has a negative result: do the authors expect substantially more favorable results? Authors' response: The meta-analysis mentioned by the reviewer (8) reported on the "mean" treatment effect of bisphosphonates in an overall knee OA population which does not take into account potential heterogeneity related to different patient or disease characteristics. That same meta-analysis and several other studies raised the question of whether the effects of bisphosphonates would be different in specific knee OA subgroups which is currently an important research gap in the literature. As described in response to comment 1 from the reviewer 1, this study aims to shed light on this question using a high-quality research design that has many advantages over existing meta-analyses with aggregate data; particularly the possibility to standardize variables and outcomes and increase the power for subgroup analyses to detect potential treatment effect modifiers. We strongly believe that patient stratification may be important for targeted treatment in knee OA since this is a highly heterogeneous condition.
3) I suppose age is also an important effect modifier, and type of bisphosphonate as well (Zol has much more potency than the oral bisphosphonates) Authors' response: We appreciate the reviewer's thoughtful suggestion. We agree that age may also be an important treatment effect modifier due to its impact on bone remodeling and thus have included it in the planned subgroup analyses. We also agree on the comment regarding bisphosphonate potency. However, due to the very low number of studies on each individual drug, we planned to stratify the analysis by nitrogeneous vs. non-nitrogenous types, since the nitrogeneous bisphosphonates have a much higher potency compared to the non-nitrogeneous ones (e.g. clodronate, etidronate).
